SCHEMBL2644070

SCHEMBL2644070

O=C(CCC1c2c(F)ccc(F)c2C(=O)N1Cc1ccc(F)cc1)Nc1nc(C(=O)O)cs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 4/20 0.39
MAPK1 P28482 3/20 0.39
PRKACA P17612 1/20 0.37
ROCK1 Q13464 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
P2RX3 P56373 1/20 0.35
MMP2 P08253 2/20 0.34
MMP1 P03956 1/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645455 0.89 CYP1A2 (0.48) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL2643283 0.89 LMNA (0.40) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL2644029 0.83 GAA (0.52) KMT2AMEN1LMNAALDH1A1L3MBTL1
SCHEMBL2643670 0.79 L3MBTL1 (0.38) LMNAALDH1A1HDAC6L3MBTL1
SCHEMBL2643817 0.78 HTT (0.37) KMT2AMEN1MAPT
SCHEMBL2664941 0.77 LMNA (0.41) RAB9ANPC1LMNAMAPK1L3MBTL1
SCHEMBL2643758 0.74 HIF1A (0.41) RAB9ANPC1ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL2643711 0.70 CCNE1 (0.41) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL2664950 0.69 MAPT (0.35) KMT2AMEN1ALDH1A1MAPT
SCHEMBL2643302 0.68 MAPT (0.38) RAB9ANPC1LMNAALDH1A1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase GCK, GCKR, GPR119 KMT2A 2178/4885MEN1 4234/4885RAB9A 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.